Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 78-90

  Tanida, Tsukasa ^a   Tanemura, Masahiro ^a,c   Miyoshi, Eiji ^b   Nagano, Hiroaki ^a   Furukawa, Kenta ^a   Nonaka, Yuji ^b   Akita, Hirofumi ^a   Hama, Naoki ^a   Wada, Hiroshi ^a   Kawamoto, Koichi ^a   Kobayashi, Shogo ^a   Eguchi, Hidetoshi ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a Kyoto University   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

Author keywords

3 galactosyltransferase; Cancer stem cells; Cancer vaccine; Immunotherapy; Pancreatic cancer; 1; gal epitopes

Indexed keywords

ALPHA GALACTOSIDASE; CANCER VACCINE; CELL EXTRACT; EPITOPE; TUMOR ANTIGEN;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER STEM CELL; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; MOUSE; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; SCID MOUSE; SYNTHESIS; TUMOR CELL CULTURE;

ALPHA-GALACTOSIDASE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL EXTRACTS; EPITOPES; GENETIC ENGINEERING; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84917711068     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2717     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Lepisto AJ, Moser AJ, Zeh H, et al: A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 6: 955-964, 2008.
3. Gjertsen MK, Bakka A, Breivik J, et al: Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346: 1399-1400, 1995.
4. Laheru D and Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 5: 459-467, 2005.
5. Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868, 2001.
6. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002.
7. Soares KC, Zheng L, Edil B and Jaffee EM: Vaccines for pancreatic cancer. Cancer J 18: 642-652, 2012.
8. Galili U, Clark MR, Shohet SB, Buehler J and Macher BA: Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1→3Gal epitope in primates. Proc Natl Acad Sci USA 84: 1369-1373, 1987.
9. Tanemura M, Yin D, Chong AS and Galili U: Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest 105: 301-310, 2000.
10. Tanemura M, Saga A, Kawamoto K, et al: In vitro and in vivo prevention of human CD8+ CTL-mediated xenocytotoxicity by pig c-FLIP expression in porcine endothelial cells. Am J Transplant 8: 288-297, 2008.
11. Galili U and LaTemple DC: Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today 18: 281-285, 1997.
12. Deguchi T, Tanemura M, Miyoshi E, et al: Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res 70: 5259-5269, 2010.
13. Wang Z, Li Y, Ahmad A, et al: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2011.
14. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
15. LaTemple DC and Galili U: Adult and neonatal anti-Gal response in knock-out mice for alpha1, 3-galactosyltransferase. Xenotransplantation 5: 191-196, 1998.
16. Thall AD, Maly P and Lowe JB: Oocyte Gal alpha 1, 3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 270: 21437-21440, 1995.
17. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M and Kloppel G: A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452, 2003.
18. LaTemple DC, Henion TR, Anaraki F and Galili U: Synthesis of alpha-galactosyl epitopes by recombinant alpha1, 3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 56: 3069-3074, 1996.
19. Tanemura M, Maruyama S and Galili U: Differential expression of alpha-GAL epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on pig and mouse organs. Transplantation 69: 187-190, 2000.
20. Kawamoto K, Tanemura M, Nishida T, Fukuzawa M, Ito T and Matsuda H: Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen. Transplantation 81: 789-796, 2006.
21. LaTemple DC, Abrams JT, Zhang SY and Galili U: Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1, 3-galactosyltransferase. Cancer Res 59: 3417-3423, 1999.
22. Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200: 297-306, 2004.
23. Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19: 145-156, 2001.
24. Hassan R and Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53, 2008.
25. Galili U, Chen ZC and DeGeest K: Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. Gynecol Oncol 90: 100-108, 2003.
26. Ladjemi MZ, Jacot W, Chardes T, Pelegrin A and Navarro- Teulon I: Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59: 1295-1312, 2010.
27. Tang CK, Katsara M and Apostolopoulos V: Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 7: 963-975, 2008.
28. Liu JP, Chen W, Schwarer AP and Li H: Telomerase in cancer immunotherapy. Biochim Biophys Acta 1805: 35-42, 2010.
29. Ryan BM, O'Donovan N and Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-562, 2009.
30. Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J and Palucka AK: Cross-priming of cyclin B1, MUC-1 and survivinspecific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res 8: R65, 2006.
31. Schnurr M, Scholz C, Rothenfusser S, et al: Apoptotic pancreatic tumor cells are superior to cell lysates in promoting crosspriming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 62: 2347-2352, 2002.
32. B ohnenkamp HR, Coleman J, Burchell JM, Taylor- Papadimitriou J and Noll T: Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol 231: 112-125, 2004.
33. Palucka AK, Ueno H, Connolly J, et al: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29: 545-557, 2006.
34. Fields RC, Shimizu K and Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95: 9482-9487, 1998.
35. B rossart P and Bevan MJ: Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90: 1594-1599, 1997.
36. Shen Z, Reznikoff G, Dranoff G and Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158: 2723-2730, 1997.
37. Shakhar G and Ben-Eliyahu S: Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10: 972-992, 2003.
38. Weighardt H, Heidecke CD, Emmanuilidis K, et al: Sepsis after major visceral surgery is associated with sustained and interferon- gamma-resistant defects of monocyte cytokine production. Surgery 127: 309-315, 2000.
39. Livingston P: The unfulfilled promise of melanoma vaccines. Clin Cancer Res 7: 1837-1838, 2001.
40. Khong HT and Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 3: 999-1005, 2002.
41. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002.
42. Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113, 2010.
43. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117, 2010.